Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617880 | 0.86 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL2692748 | 0.86 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL2692741 | 0.86 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL2692744 | 0.86 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL66496 | 0.85 | BRD4 (0.43) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL5652849 | 0.85 | BRD4 (0.43) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL7242578 | 0.85 | FUCA1 (0.50) | GRIN2BS1PR1S1PR5ACHEOPRM1 | |
| SCHEMBL4132636 | 0.80 | KCNH2 (0.43) | GRIN2BS1PR1S1PR5ACHEFUCA1 | |
| SCHEMBL7248714 | 0.80 | FUCA1 (0.46) | GRIN2BS1PR1S1PR5ACHEFUCA1 | |
| SCHEMBL1307812 | 0.79 | OPRM1 (0.55) | ACHEOPRM1BCHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | GRIN2B 1852/4885S1PR1 4476/4885S1PR5 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.